
Sanofi completes acquisition of Vigil Neuroscience
Sanofi has completed its acquisition of Vigil Neuroscience, adding VG-3927, a novel, oral, small-molecule TREM2 agonist, to Sanofi’s neurology pipeline. Vigil is a clinical-stage biotechnology company targeting neurodegenerative diseases through disease-modifying therapeutics that restore the vigilance of microglia. Sanofi will also acquire Vigil’s preclinical pipeline… Read More
